Physician profile
Brandi E Guthrey
NPI 1073712212
$8,399.64
in general payments reported to CMS, 2019-2025
41 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $1,477 · 2021: $1,800 · 2022: $1,545 · 2023: $450 · 2024: $937 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,310.17 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $905.15 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $898.74 | 2019-2024 | Otezla, Repatha, Prolia |
| Allergan, INC. | $459.47 | 2019-2020 | |
| Abbvie INC. | $446.01 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $411.51 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $402.57 | 2019-2021 | |
| Lilly USA, LLC | $371.10 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $350.81 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $333.86 | 2021 | |
| Glaxosmithkline, LLC. | $271.63 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $205.54 | 2020-2025 | Freestyle Libre, Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $205.00 | 2020-2021 | |
| Abiomed | $165.11 | 2024 | Impella |
| Medtronic, INC. | $129.44 | 2022-2024 | Interstim |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Guthrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.